Quince Therapeutics Explores Strategic Alternatives After Clinical Setback

Cortexyme US22053A1079

Following the failure of its lead clinical candidate, Quince Therapeutics has initiated a formal review of its strategic options. The move, which includes hiring an exclusive financial advisor, signals the company’s openness to a potential sale or merger as it seeks to navigate a significant challenge.

• The firm has mandated LifeSci Capital to explore avenues such as mergers, asset sales, or partnerships.
• Its share price has recovered from a 52-week low of $0.13 to recently trade at $0.53.
• This strategic pivot was triggered by the discontinuation of the Phase 3 NEAT study in late January.